(-0.08%) 5 304.25 points
(-0.09%) 40 140 points
(-0.05%) 18 465 points
(-0.07%) $83.11
(-0.62%) $1.752
(0.73%) $2 254.80
(0.74%) $25.10
(0.21%) $923.00
(0.12%) $0.928
(0.14%) $10.86
(0.01%) $0.792
(-0.07%) $92.51
Live Chart Being Loaded With Signals
Taiko Pharmaceutical Co.,Ltd. engages in pharmaceuticals, infection control, and other businesses. The company manufactures and sells non-prescription drugs under the Seirogan and Seirogan Toi-A brands for the treatment of loose stools, diarrhea, food and water poisoning, vomiting, and related conditions; tablets for diarrhea; and quasi-drugs, such as Trumpet Intestinal Regulator BF...
Stats | |
---|---|
Today's Volume | 129 500 |
Average Volume | 506 661 |
Market Cap | 19.46B |
EPS | ¥0 ( 2024-02-08 ) |
Next earnings date | ( ¥0 ) 2024-05-09 |
Last Dividend | ¥13.00 ( 2021-12-29 ) |
Next Dividend | ¥0 ( N/A ) |
P/E | -7.55 |
ATR14 | ¥0.526 (0.14%) |
Volume Correlation
Taiko Pharmaceutical Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Taiko Pharmaceutical Correlation - Currency/Commodity
Taiko Pharmaceutical Financials
Annual | 2022 |
Revenue: | ¥5.04B |
Gross Profit: | ¥1.08B (21.41 %) |
EPS: | ¥-112.24 |
Q3 | 2023 |
Revenue: | ¥1.93B |
Gross Profit: | ¥740.00M (38.36 %) |
EPS: | ¥0 |
Q2 | 2023 |
Revenue: | ¥1.32B |
Gross Profit: | ¥477.00M (36.11 %) |
EPS: | ¥-5.76 |
Q1 | 2023 |
Revenue: | ¥1.17B |
Gross Profit: | ¥574.00M (49.19 %) |
EPS: | ¥-5.57 |
Financial Reports:
No articles found.
Taiko Pharmaceutical Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
First Dividend | ¥0.556 | 2009-03-26 |
Last Dividend | ¥13.00 | 2021-12-29 |
Next Dividend | ¥0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 18 | -- |
Total Paid Out | ¥72.22 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 1.18 | -- |
Div. Sustainability Score | 0.484 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
9543.T | Ex Dividend Knight | 2023-12-28 | Semi-Annually | 0 | 0.00% | |
8595.T | Ex Dividend Junior | 2023-03-30 | Annually | 0 | 0.00% | |
7937.T | Ex Dividend Junior | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
7186.T | Ex Dividend Junior | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
6472.T | Ex Dividend Junior | 2023-09-28 | Annually | 0 | 0.00% | |
5706.T | Ex Dividend Junior | 2023-09-28 | Annually | 0 | 0.00% | |
4536.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
3773.T | Ex Dividend Junior | 2023-03-30 | Insufficient data to determine frequency | 0 | 0.00% | |
3050.T | Ex Dividend Junior | 2023-08-30 | Semi-Annually | 0 | 0.00% | |
1949.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.375 | 1.500 | -7.50 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -0.144 | 1.200 | -4.80 | -5.76 | [0 - 0.3] |
returnOnEquityTTM | -0.261 | 1.500 | -4.01 | -6.02 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 3.19 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 2.54 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 1.719 | 1.500 | 1.560 | 2.34 | [0.2 - 2] |
debtRatioTTM | 0.188 | -1.500 | 6.86 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -85.89 | 1.000 | -10.00 | -10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 0 | 2.00 | 0 | 0 | [0 - 30] |
freeCashFlowPerShareTTM | 0 | 2.00 | 0 | 0 | [0 - 20] |
debtEquityRatioTTM | 0.305 | -1.500 | 8.78 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.394 | 1.000 | 6.76 | 6.76 | [0.2 - 0.8] |
operatingProfitMarginTTM | -0.127 | 1.000 | -4.55 | -4.55 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0 | 1.000 | -1.111 | -1.111 | [0.2 - 2] |
assetTurnoverTTM | 0.384 | 0.800 | -0.775 | -0.620 | [0.5 - 2] |
Total Score | 0.484 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -7.61 | 1.000 | -0.870 | 0 | [1 - 100] |
returnOnEquityTTM | -0.261 | 2.50 | -2.58 | -6.02 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0 | 2.00 | 0 | 0 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0 | 2.00 | 0 | 0 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.0627 | 1.500 | -3.75 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0 | 1.000 | -2.50 | 0 | [0.1 - 0.5] |
Total Score | -1.545 |
Taiko Pharmaceutical
Taiko Pharmaceutical Co.,Ltd. engages in pharmaceuticals, infection control, and other businesses. The company manufactures and sells non-prescription drugs under the Seirogan and Seirogan Toi-A brands for the treatment of loose stools, diarrhea, food and water poisoning, vomiting, and related conditions; tablets for diarrhea; and quasi-drugs, such as Trumpet Intestinal Regulator BF. It also manufactures and sells sanitation control products under the Cleverin brand name to wholesalers, as well as Cleverin generator, a machine that emits low concentrations of chlorine dioxide gas; and supplies products using the patented Cleverin technology through OEM agreements and products developed jointly with other companies. It exports its products to the United States, Canada, Thailand, Vietnam, Malaysia, and Mongolia. Taiko Pharmaceutical Co.,Ltd. was incorporated in 1946 and is headquartered in Osaka, Japan.`
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators